In both data sets, the impact of EZH2 expression remained significant on multivariate analysis (Supplementary Tables S1 and S2), demonstrating its effect is independent of other factors known to affect survival in myeloma patients including International Staging System, GEP70 risk and adverse cytogenetics. The gene discussed is EZH2; the disease is plasma cell myeloma.